1. Aging, rather than Parkinson's disease, affects the responsiveness of PBMCs to the immunosuppression of bone marrow mesenchymal stem cells
- Author
-
Xiaobo Li, Chun‑Song Zhao, Yu Alex Zhang, Hai‑Qiang Zou, Xiao‑Ming Yan, Jia‑Lin Wu, Yun‑Qian Guan, and Lu‑Lu Luo
- Subjects
Adult ,Male ,0301 basic medicine ,Aging ,Cancer Research ,bone marrow ,medicine.medical_treatment ,Interleukin-1beta ,Biochemistry ,Peripheral blood mononuclear cell ,Proinflammatory cytokine ,Interferon-gamma ,03 medical and health sciences ,0302 clinical medicine ,Parkinsons disease ,Interleukin-1alpha ,Genetics ,medicine ,Humans ,Molecular Biology ,Cell Proliferation ,Immunosuppression Therapy ,mesenchymal stem cells ,Interleukin-6 ,Tumor Necrosis Factor-alpha ,business.industry ,Interleukin ,Parkinson Disease ,Immunosuppression ,Articles ,Middle Aged ,Coculture Techniques ,Transplantation ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,inflammation ,Immunology ,Leukocytes, Mononuclear ,Molecular Medicine ,Cytokine secretion ,Tumor necrosis factor alpha ,Bone marrow ,business ,Immunosuppressive Agents ,030217 neurology & neurosurgery ,transplantation - Abstract
Whether aging or Parkinson's disease (PD) affects the responses of peripheral blood mononuclear cells (PBMCs) to immunosuppression by bone marrow-derived mesenchymal stem cell (BM-MSCs) and which cytokines are more effective in inducing BM-MSCs to be immunosuppressive remains to be elucidated. PBMCs were isolated from healthy young (age 26–35), healthy middle-aged (age 56–60) and middle-aged PD-affected individuals. All the recruits were male. The mitogen-stimulated PBMCs and proinflammatory cytokine-pretreated BM-MSCs were co-cultured. The PBMC proliferation was measured using Cell Counting Kit-8, while the cytokine secretion was assayed by cytometric bead array technology. The immunosuppressive ability of BM-MSCs was confirmed in young healthy, middle-aged healthy and middle-aged PD-affected individuals. Among the three groups, the PBMC proliferation and cytokine secretion of the young healthy group were suppressed more significantly compared with those of the middle-aged healthy and middle-aged PD-affected group. No significant differences were identified in the PBMC proliferation and cytokine secretion between the patients with PD and the middle-aged healthy subjects. Interferon (IFN)-γ synergized with tumor necrosis factor (TNF)-α, interleukin (IL)-1α or IL-1β was more effective than either one alone, and the combinations of IFN-γ + IL-1α and IFN-γ + IL-1β were more effective than IFN-γ + TNF-α in inducing BM-MSCs to inhibit PBMC proliferation. The results of the present study suggested that aging, rather than PD, affects the response of PBMCs toward the suppression of BM-MSC, at least in middle-aged males. Patients with PD aged 56–60 remain eligible for anti-inflammatory BM-MSC-based therapy. Treatment of BM-MSCs with IFN-γ + IL-1α or IFN-γ + IL-1β prior to transplantation may result in improved immunosuppressive effects.
- Published
- 2018
- Full Text
- View/download PDF